BofA/Merrill Lynch Upgrades Myriad Genetics (MYGN) to Buy
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $3.20 -0.62%
Rating Summary:
7 Buy, 19 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
7 Buy, 19 Hold, 4 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
BofA/Merrill Lynch upgraded Myriad Genetics (NASDAQ: MYGN) from Neutral to Buy.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $25.37 yesterday.
For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.
Shares of Myriad Genetics closed at $25.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts Mobility Global (MBGL) at Neutral
- BofA truck shipper survey shows demand outlook rises modestly
- Royal Caribbean completes $1.25B senior unsecured notes offering
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
